**OxyContin® References:**

Please Note:

* Reference # 3 and 60 are databases and are therefore not included.
* References # 43 and 44 are only available in abstract form (poster presentation).

**References**

1. OxyContin® [package insert]. Stamford (CT): Purdue Pharma, LP: 2015 Aug.
2. OxyContin® (oxycodone extended-release) product Dossier. 2015. Version 3.1. Purdue. Data on file.
3. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Reuters (Healthcare) Inc.; Updated periodically [cited 2015 Nov 30]. Available from: <http://www.thomsonhc.com/>.
4. Bercovitch M, Adunsky A. High dose controlled-release oxycodone in hospice care. *J Pain Palliat Care Pharmacother*. 2006;20(4):33-39.
5. Berger A, Hoffman DL, Goodman S, et al. Therapy switching in patients receiving long-acting opioids. *Ann Pharmacother*. 2004;38(3):389-395.
6. Binsfeld H, Szczepanski L, Waechter S, Richarz U, Sabatowski R. A randomized study to demonstrate noninferiority of once-daily OROS hydromorphone with twice-daily sustained release oxycodone for moderate to severe chronic noncancer pain. *Pain Pract*. 2010;10:404-415.
7. Bruera E, Belzile M, Pituskin E, et al. Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. *J Clin Oncol.* 1998;16(10):3222-3229.
8. Caldwell JR, Hale ME, Boyd RE, et al. Treatment of osteoarthritis pain with controlled release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal anti-inflammatory drugs: a double blind, randomized, multicenter, placebo controlled trial. *J Rheumatol.* 1999;26(4):862-869.
9. Cheville A, Chen A, Oster G, et al. A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. *J Bone Joint Surg Am.* 2001;83-A(4):572-576.
10. Citron ML, Kaplan R, Parris WCV, et al. Long-term administration of controlled-release oxycodone tablets for the treatment of cancer pain. *Cancer Invest.* 1998;16(8):562-571.
11. de Beer J , Winemaker MJ , Donnelly GAE , et al. Efficacy and safety of controlled-release oxycodone and standard therapies for postoperative pain after knee or hip replacement. *Can J Surg.* 2005;48(4):277-283.187
12. Dworkin RH, Barbano RL, Tyring SK, et al. A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. *Pain*. 2009;142(3):209-217.
13. Ferrares F, Becchimanzi G, Bernardo M, et al. Pain treatment with high-dose, controlled-release oxycodone: an Italian perspective. *Ther Clin Risk Manag*. 2008;4(4):665-671.
14. Gatti A, Longo G, Sabato E, Sabato AF. Long-term controlled-release oxycodone and pregabalin in the treatment of non-cancer pain: an observational study. *Eur Neurol*. 2011;65(6):317-322.
15. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. *Neurology.* 2003;60(6):927-934.
16. Ginsberg B, Sinatra RS, Adler LJ, et al. Conversion to oral controlled-release oxycodone from intravenous opioid analgesic in the postoperative setting. *Pain Med.* 2003;4(1):31-38.
17. Giuggioli D, Manfredi A, Colaci M, Ferri C. Oxycodone in the long-term treatment of chronic pain related to scleroderma skin ulcers. *Pain Med*. 2010;11(10):1500-1503.
18. Hale ME, Fleischmann R, Salzman R, et al. Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain. *Clin J Pain.* 1999;15(3): 179-183.
19. Illgen RL. Pellino TA, Gordon DB, et al. Prospective analysis of a novel long-acting oral opioid analgesic regimen for pain control after total hip and knee arthroplasty*. J Arthroplasty.* 2006. 21(6):814-820.
20. Kampe S, Warm M, Kaufmann J, et al. Clinical efficacy of controlled-release oxycodone 20mg administered on a 12-h dosing schedule on the management of postoperative pain after breast surgery for cancer. *Curr Med Res Opin.* 2004;20(2): 199-202.
21. Kampe S, Wolter K, Warm M, Dagtekin O, Shaheen S, Landwehr S. Clinical equivalence of controlled-release oxycodone 20 mg and controlled-release tramadol 200 mg after surgery for breast cancer. *Pharmacology*. 2009;84(5):276-281.
22. Kaplan R, Parris WCV, Citron ML, et al. Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. *J Clin Oncol*. 1998;16(10):3230-3237.
23. Li X-M, Liu D-Q,Wu H-Y,Yang C, Yang L. Controlled-release oxycodone alone or combined with gabapentin for management of malignant neuropathic pain. *Chin J Cancer Res*. 2010;22(1):80-86.
24. Markenson JA, Croft J, Zhang PG, Richards P. Treatment of persistent pain associated with osteoarthritis with controlled-release oxycodone tablets in a randomized controlled clinical trial. *Clin J Pain*. 2005;21(6):524-535.
25. Mercadante S, Ferrera P, David F, Casuccio A. The use of high doses of oxycodone in an acute palliative care unit. *Am J Hosp Palliat Care*. 2011;28:242-244.
26. Mucci-LoRusso P, Berman BS, Silberstein PT, et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. *Eur J Pain*. 1998;2(3):239-249.
27. Parris WC-V, Johnson BW, Croghan MK, Moore MR, Khojasteh A, Reder RF, Kaiko RF, Buckley BJ. The use of controlled-release oxycodone for the treatment of chronic cancer pain: A randomized, double blind study. *J Pain Symptom Manage*.1998;16(4):205-211.
28. Portenoy RK, Farrar JT, Backonja MM, et al. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study. *Clin J Pain*. 2007;23(4):287-299.
29. Ravera E, Di Santo S, Bosco R, Arboscello C, Chiarlone R. Controlled-release oxycodone tablets after transdermal-based opioid therapy in patients with cancer and non-cancer pain. *Aging Clin Exp Res*. 2011;23(5-6):328-332.
30. Richarz U, Waechter S, Sabatowski R, Szczepanski L, Binsfeld H. Sustained safety and efficacy of once-daily hydromorphone extended-release (OROS® hydromorphone ER) compared with twice-daily oxycodone controlled-release over 52 weeks in patients with moderate to severe chronic noncancer pain. *Pain Pract*. 2013 Jan;13(1):30-40.
31. Ried CM, Martin RM, Sterne JA, et al. Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials. *Arch Intern Med*. 2006;166(21):837-843.
32. Riley J, Eisenberg E, Muller-Schwefe G, et al. Oxycodone: a review of its use in the management of pain. *Curr Med Res Opin*. 2008;24(1):175-192.
33. Rischitelli DG, Karbowicz SH. Safety and efficacy of controlled-release oxycodone: a systematic literature review. *Pharmacotherapy*. 2002;22(7):989-904.
34. Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: Placebo-controlled trial and long-term evaluation. *Arch Intern Med*. 2000;160(6): 853-860.
35. Rothwell MP, Pearson D, Hunter JD, et al. Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority stud Stambaugh JE, Reder RF, Stambaugh MD, et al. Double-blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled- and immediate- release oral oxycodone in cancer pain patients. *J Clin Pharmacol.* 2001;41(5):500-506.
36. Watson CPN, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. *Neurology.* 1998;50(6):1837-1841.
37. Watson CPN, Moulin D, WW J, et al. Controlled-release oxycodone relieves neuropathic pain: a randomized controlled trial in painful diabetic neuropathy. *Pain*. 2003;105(1-2):71-78. y. *Br J Anaesth*. 2011;106(6):865-872.
38. Wild EJ, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. *Pain Practice*. 2010;10(5):416-427.
39. Wirz S, Wartenberg H, Wittmann M, Nadstawek J. Post-operative pain therapy with controlled-release oxycodone or controlled release tramadol following orthopedic surgery: A prospective, randomized, double-blind investigation. *The Pain Clinic*. 2005;17(4):367-376.
40. Yao P, Meng LX, Ma JM, et al. Sustained-release oxycodone tablets for moderate to severe painful diabetic peripheral neuropathy: A multicenter, open-labeled, postmarketing clinical observation. *Pain Med*. 2012;13(1):107-114.
41. Zhou B, Wang J, Yan Z, Shi P, Kan Z. Liver cancer: effects, safety, and cost-effectiveness of controlled-release oxycodone for pain control after TACE. *Radiology*. 2012 Mar;262(3):1014-21.
42. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. *J Pain*. 2013;14(4):351-358.
43. Chilcoat H, Coplan P, Cassidy TA, Black RA, Landau C, Budman SH, Butler SF. Impact of reformulated OxyContin on rates of abuse through oral and non-oral routes among individuals assessed in substance abuse treatment [poster]. Presented at: 74th Annual Scientific Meeting of the College on Problems of Drug Dependence; June 9-14, 2012, Palm Springs, CA. Abstract #103.
44. Cassidy TA, Coplan P, Black RA, Chilcoat H, Budman SH, Butler SF. Change in routes of administration for OxyContin and comparators following introduction of reformulated OxyContin among individuals assessed for substance abuse [poster]. Presented at: 74th Annual Scientific Meeting of the College on Problems of Drug Dependence; June 9-14, 2012, Palm Springs, CA. Abstract #88.
45. FDA Approves Abuse-deterrent Labeling for Reformulated OxyContin [press release on the internet]. Rockville (MD): Food and Drug Administration (US): 2013 Apr [cited 2015 Nov 30]. Available from: <http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm348252.htm>.
46. Food and Drug Administration Center for Drug Evaluation and Research (CDER) Joint Meeting of the Anesthetic and Life Support Drugs Advisory Committee (ALSDAC) and the Drug Safety and Risk Management Advisory Committee (DSaRM) [press release on the Internet]. Rockville (MD): FDA: 2009 Sep 24 [cited 2015 Dec 22]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndLifeSupportDrugsAdvisoryCommittee/UCM187629.pdf.
47. FDA Approves New Formulation for OxyContin [press release on the internet]. Rockville (MD): Food and Drug Administration (US): 2010 Apr [cited 2015 Nov 30]. Available from: <http://www.fda.gov/newsevents/newsroom/PressAnnouncements/ucm207480.htm>.
48. Purdue Pharma L.P. comments on FDA announcement on REMS For extended-release and long-acting opioid analgesics [press release on the Internet]. Stamford (CT): Purdue Pharma L.P.: 2012 Jul 9 [cited 2015 Dec 22]. Available from: <http://www.purduepharma.com/news-media/2012/07/purdue-pharma-l-p-comments-on-fda-announcement-on-rems-for-extended-release-and-long-acting-opioid-analgesics/>.
49. Cone EJ, Giordano J, Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend. 2013; 131:100-105.

Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, and Sellers EM. Abuse Potential, Pharmacokinetics, Pharmacodynamics, and Safety of Intranasally Administered Crushed Oxycodone HCl Abuse‐Deterrent Controlled‐Release Tablets in Recreational Opioid Users. The Journal of Clinical Pharmacology; 54(4):468-77

Perrino PJ, Colucci SV, Apseloff G, Harris SC. Pharmacokinetics, tolerability and safety of intranasal administration of reformulated OxyContin tablets compared with original OxyContin tablets in healthy adults. Clin Drug Investig. 2013; 33:441-49.

Gudin J, Levy-Cooperman N, Kopecky EA and Fleming AB. Comparing the effect of tampering on the oral pharmacokinetic profiles of two extended-release oxycodone formulations with abuse-deterrent properties. Pain Med. 2015 Jun; 16:2142-51. doi:10.1111/pme.12834. [Epub ahead of print]

FDA gives tentative approval to abuse-deterrent Xtampza ER. [press release on the Internet]. FDA.gov. 2015 Nov 9 [cited 2015 Dec 2]. Available from: <http://www.medscape.com/viewarticle/854181>.

1. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J

Med. 2012;367(2):187-189.

1. Coplan PM, Kale H, Sandstrom L, Landau C, Chilcoat HD. Changes in oxycodone and heroin

exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013;22(12):1274-1282.

1. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2013;14(4):351-358.
2. Severtson SG, Bartelson BB, Davis JM, et al. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013;14(10):1122-1130.
3. Sessler NE, Downing JM, Kale H, Chilcoat HD, Baumgartner TF, Coplan PM. Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014;23(12):1238-1246.
4. Cicero TJ, Ellis MS. Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States. JAMA Psychiatry. 2015;72(5):424-29.
5. Bluelight [homepage on the Internet]. 2010 Sep 25 [cited 2015 Dec 22]. Available from: <http://www.bluelight.org/vb/threads/526460-Method-for-snorting-IV-OP-OxyContin>.

Purdue pulls new OxyContin application and questions follow [press release on the Internet]. MedPage Today; 2015 Jul 2 [cited 2015 Dec 22]. Available from: <http://www.medpagetoday.com/Neurology/GeneralNeurology/52431>.

Postmarket requirements and commitments. Silver Spring (MD): Food and Drug Administration; 2013 Aug 9 [cited 2015 Dec 22]. Available from: https://www.documentcloud.org/documents/2157297-oxypostmarket.html.

U.S. Food and Drug Administration. Guidance for industry: abuse-deterrent opioids--evaluation and labeling. Silver Spring (MD): Food and Drug Administration; 2015 Apr [cited 2015 Dec 1]. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM334743.pdf.

U.S. Food and Drug Administration. Opioid Medications; Information on Opioid Medications. Silver Spring (MD): Food and Drug Administration; 2015 Nov 25 [cited 2015 Dec 3]. Available from: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm337066.htm.

Roth SH, Fleischmann RM, Burch FX, et al. Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation. Arch Intern Med. 2000; 160(6):853-60.

1. An Open-label, Multicenter Study of the Safety of Twice Daily Oxycodone Hydrochloride Controlled-release Tablets in Opioid Experienced Children From Ages 6 to 16 Years Old, Inclusive, With Moderate to Severe Malignant and/or Nonmalignant Pain Requiring Opioid Analgesics (OTR3001). Data on File [OTR3001]. Stamford, CT: Purdue Pharma L.P.
2. Vuilleumier PH, Stamer UM and Landau R. Pharmacogenomic considerations in opioid analgesia. Pharmacogenomics and Personalized Medicine. 2012;5:73-87.